Pharmaceuticals, Inc. (NASDAQ: TTPH) , a clinical-stage
biopharmaceutical company whose lead product candidate, eravacycline, is
being developed as a broad-spectrum intravenous and oral antibiotic
designed to be effective against dangerous, drug-resistant bacteria
(including multidrug-resistant (MDR) Gram-negative pathogens), today
announced its participation in two upcoming investor conferences:
A live audio webcast of the Stifel presentation will be available on the
Company's website at http://ir.tphase.com/events.cfm .
Starwood Waypoint Residential Trust (NYSE:SWAY) (the “Company”), a
leading single-family rental real estate investment trust (“REIT”),
today announced its operating and financial results for the third
bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to
developing potentially transformative gene therapies for severe genetic
and orphan diseases, today reported financial results and operational
highlights for the quarter ended September 30, 2014.
The Alpha Omega-Henry Schein Cares Holocaust Survivors Oral Health Program, a pilot initiative, will provide pro-bono oral care for 250-300 Holocaust survivors across nine North American cities
MELVILLE, N.Y. , Nov.
Aradigm Corporation (Nasdaq:ARDM) (the “Company”) today announced
that Igor Gonda, Aradigm’s President and Chief Executive Officer, will
present an overview of the Company at the Stifel Healthcare Conference
2014 at the New York Palace Hotel in New York, New York on Tuesday,
November 18, 2014 at 8:00 am Eastern time.
Installed Building Products, Inc. (the “Company” or “IBP”) (NYSE:IBP),
an industry-leading installer of insulation and complementary building
products, announced today results for the third quarter ended September
Acorda Therapeutics, Inc. (Nasdaq: ACOR )
today announced that Ron Cohen, M.D., President and Chief Executive
Officer will present at the Stifel 2014 Healthcare Conference on
Tuesday, November 18 at 1:50pm ET.
Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on
the development and commercialization of innovative therapies for
diseases and conditions of the eye, today announced financial results
for the third quarter ended September 30, 2014, and provided an update
on current business developments.
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with
fully integrated commercial and drug development operations with a
primary focus in hematology and oncology, today announced that an
overview of the Company's business strategy and commercial and
development-stage programs will be given at the Jefferies 2014 Global
London Healthcare Conference in London.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.